Clinical Trials

Trial results and what they actually showed.

June 5, 2026

Novo Nordisk's Zenagamtide Pairs GLP-1 With Amylin in One Molecule, Cutting A1C and Weight in a Phase 2 Trial

The first single-molecule drug to combine GLP-1 and amylin activation showed meaningful glucose and weight effects in type 2 diabetes, an early signal of the field's move into amylin-based therapy.
May 21, 2026

Retatrutide, Lilly's Triple-Hormone Agonist, Posts 28% Weight Loss in Its Pivotal Obesity Trial

The largest and longest trial yet of a drug that hits three gut-hormone receptors at once points to a new efficiency ceiling for obesity medicines, though these are topline results, not yet peer-reviewed.

Novo Nordisk's Zenagamtide Pairs GLP-1 With Amylin in One Molecule, Cutting A1C and Weight in a Phase 2 Trial